Metabolite is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-23. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
The medals were presented to Cotchin and Mitchell in a small ceremony in Melbourne on 13 December 2016. Watson's physical medal was handed back to the AFL CEO Gillon McLachlan in early 2017, with no plans in place to re-present or display it as of February 2017.
Jung noted that, occasionally, such experiences had been known to reform alcoholics when all other options had failed. Hazard took Jung's advice seriously and sought a personal, spiritual experience. He returned to the United States and joined a Christian evangelical movement known as the Oxford Group. He told other alcoholics what Jung had told him about the importance of a spiritual experience. One of the alcoholics he brought into the Oxford Group was Ebby Thacher, a long-time friend and drinking buddy of William Griffith Wilson, later co-founder of Alcoholics Anonymous. Thacher told Wilson about the Oxford Group, and through them, Wilson became aware of Hazard's experience with Jung. The influence of Jung thus indirectly found its way into the formation of Alcoholics Anonymous, the original twelve-step program. The above claims are documented in the letters of Jung and Wilson. Although some historians dispute the detail, Jung discussed an Oxford Group member, who may have been the same person, in talks around 1940. The remarks were distributed privately in transcript form, from shorthand taken by an attender (Jung reportedly approved the transcript), and later recorded in his Collected Works, "For instance, when a member of the Oxford Group comes to me in order to get treatment, I say, 'You are in the Oxford Group; so long as you are there, you settle your affair with the Oxford Group. I can't do it better than Jesus.'" Jung goes on to state he has seen similar cures among Roman Catholics.
== Posthumous recognition == In 1959 she became the first woman elected to the Poultry Historical Society Hall of Fame. She was inducted into the National Women's Hall of Fame in 2002, the American Society of Heating, Refrigerating and Air-Conditioning Engineers Hall of Fame in 2007, and the National Inventors Hall of Fame in 2018.
Sources: en.wikipedia.org
Physical presence may be required for women who are in relationships for the testosterone–partner interaction, where same-city partnered women have lower testosterone levels than long-distance partnered women.
Multiple drugs from each category have been proven effective. Marketized drugs have encountered market demands, also boosted personalized medication developments aiming at a broader range of recipients. Still, disease establishment dilemmas and FDA drug approvals give rise to ethical concerns, posing obstacles in the field's development.
Geranylgeranyl diphosphate reductase (EC 1.3.1.83, geranylgeranyl reductase, CHL P) is an enzyme with systematic name geranylgeranyl-diphosphate:NADP+ oxidoreductase. This enzyme catalyses the following chemical reaction
== Applications in antimicrobial development == Over the last twenty years, there has been increasing interest in leveraging inteins for antimicrobial applications. Intein splicing is found exclusively in unicellular organisms, with a particularly high abundance in pathogenic microorganisms. Furthermore, inteins are commonly found within housekeeping proteins and/or proteins involved in the survival of the organism within a human host. Post-translational intein removal is necessary for the protein to properly fold and function. For example, Gaëlle Huet et al. demonstrated that in Mycobacterium tuberculosis, unspliced SufB prevents the formation of the SufBCD complex, a component of the SUF machinery. As such, the inhibition of intein splicing may serve as a powerful platform for the development of antimicrobials. Current research on intein splicing inhibitors has focused on developing antimycobacterials (M. tb. has three intein-containing proteins), as well as agents active against pathogenic fungi Cryptococcus and Aspergillus. Cisplatin and similar platinum-containing compounds inhibit splicing of the M. tb. RecA intein through coordinating to catalytic residues. Divalent cations, such as copper (II) and zinc (II) ions, function similarly to reversibly inhibit splicing. However, neither of these methods are currently suitable for an effective and safe antibiotic. The fungal Prp8 intein is also inhibited by divalent cations and cisplatin through interfering with the catalytic Cys1 residue. In 2021, Li et al.
Sources: en.wikipedia.org
=== EC 1.18.1 With NAD+ or NADP+ as acceptor === EC 1.18.1.1: rubredoxin—NAD+ reductase EC 1.18.1.2: ferredoxin—NADP+ reductase EC 1.18.1.3: ferredoxin—NAD+ reductase EC 1.18.1.4: rubredoxin—NAD(P)+ reductase EC 1.18.1.5: Putidaredoxin—NAD+ reductase EC 1.18.1.6: adrenodoxin-NADP+ reductase EC 1.18.1.7: ferredoxin—NAD(P)+ reductase (naphthalene dioxygenase ferredoxin-specific) EC 1.18.1.8: Now EC 7.2.1.2, ferredoxin—NAD+ oxidoreductase (Na+-transporting)
Transportation in Colombia is regulated within the functions of the Ministry of Transport and entities such as the National Roads Institute (INVÍAS) responsible for the Highways in Colombia, the Aerocivil, responsible for civil aviation and airports, the National Infrastructure Agency, in charge of concessions through public–private partnerships, for the design, construction, maintenance, operation, and administration of the transport infrastructure, the General Maritime Directorate (Dimar) has the responsibility of coordinating maritime traffic control along with the Colombian Navy, among others, and under the supervision of the Superintendency of Ports and Transport. In 2021, Colombia had 204,389 km (127,001 mi) of roads, 32,280 km (20,058 mi) of which were paved. At the end of 2017, the country had around 2,100 km (1,305 mi) of duplicated highways. Rail transportation in Colombia is dedicated almost entirely to freight shipments and the railway network has a length of 1,700 km of potentially active rails. Colombia has 3,960 kilometers of gas pipelines, 4,900 kilometers of oil pipelines, and 2,990 kilometers of refined-products pipelines. The Colombian government aimed to build 7,000 km of roads between 2016 and 2020, which would reduce travel times by an estimated 30 per cent, and transport costs by an estimated 20 per cent.
Pseudoephedrine is available by itself over-the-counter in the form of 30 and 60 mg immediate-release and 120 and 240 mg extended-release oral tablets in the United States. Pseudoephedrine is also available over-the-counter and prescription-only in combination with numerous other drugs, including antihistamines (acrivastine, azatadine, brompheniramine, cetirizine, chlorpheniramine, clemastine, desloratadine, dexbrompheniramine, diphenhydramine, fexofenadine, loratadine, triprolidine), analgesics (acetaminophen, codeine, hydrocodone, ibuprofen, naproxen), cough suppressants (dextromethorphan), and expectorants (guaifenesin). Pseudoephedrine has been used in the form of the hydrochloride and sulfate salts and in a polistirex form. The drug has been used in more than 135 over-the-counter and prescription formulations. Many prescription formulations containing pseudoephedrine have been discontinued over time.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.